ArticleJAMA internal medicine2019
Comparative Analysis of Medicines Safety Advisories Released by Australia, Canada, the United States, and the United Kingdom.
Article in JAMA internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Navigating the Prescription Drug Information System.Clinical pharmacology and therapeutics · 2026Review
- Article
- Safety Warnings on the Same Harmful Effects of Medicines: A Comparison of Four National Regulators.Pharmaceutical medicine · 2025Article
- Vitamin B12 deficiency in long-term metformin use and clinician awareness: a scoping review protocol.BMJ open · 2025Article
- Direct oral anticoagulant approvals by four major regulatory agencies: a cross-sectional analysis of premarket and postmarket evidence.BMJ open · 2024Article
- Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.BMJ (Clinical research ed.) · 2022Article
- Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study.Pharmacoepidemiology and drug safety · 2022Article
- Medicines withdrawn in other countries due to safety concerns: should they continue to be available in the Argentine pharmaceutical market?Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina) · 2022Article
- "Drugs to avoid" to improve quality use of medicines: how is Australia faring?Journal of pharmaceutical policy and practice · 2021Article
- Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.Pharmacology research & perspectives · 2020Article
- Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.Systematic reviews · 2020Article
- Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab.British journal of clinical pharmacology · 2020Article
- US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS).Pharmaceutical medicine · 2020Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.